Evidence map›Paper›PMID 35308232›Full record

ArticleFrontiers in pharmacology2022

Immunotherapy for a POLE Mutation Advanced Non-Small-Cell Lung Cancer Patient.

Yang Fu, Yue Zheng, Pei-Pei Wang, Yue-Yun Chen, Zhen-Yu Ding

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yang FuCancer Center, State Key Laboratory of Biotherapy, Department of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Yue ZhengCancer Center, State Key Laboratory of Biotherapy, Department of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Pei-Pei WangCancer Center, State Key Laboratory of Biotherapy, Department of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Yue-Yun ChenCancer Center, State Key Laboratory of Biotherapy, Department of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Zhen-Yu DingCancer Center, State Key Laboratory of Biotherapy, Department of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Sichuan University · CNState Key Laboratory of Biotherapy

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, the predictive role of POLE mutations for immunotherapy is under intense investigation. The POLE gene encodes one of the four subunits of DNA polymerase important for DNA replication and repair. POLE mutations are related to other favorable predicative factors such as high expression of PD-L1, high TMB, and infiltration of CD8

Indexed as

brain metastasesCRlung adenocarcinomaPD-L1POLE mutation

Identifiers

PMID35308232
PMCPMC8931479
OpenAlexW4214873887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.